AZN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT05456867A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice...AstraZeneca · NSCLC, Non-small-cell Lung Carcinoma | AZNLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07081633Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaAstraZeneca · Hepatocellular Carcinoma | AZNLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07218172Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)AstraZeneca · Severe Asthma | AZNLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT05456867A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice...AstraZeneca · NSCLC, Non-small-cell Lung CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT07081633Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaAstraZeneca · Hepatocellular CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07218172Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)AstraZeneca · Severe AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1NCT02826434Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerMassachusetts General Hospital · Breast CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03449251A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinCambridge University Hospitals NHS Foundation Trust · Cardiovascular DiseasesActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03965468Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCETOP IBCSG Partners Foundation · Non-small Cell Lung CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT04116047CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)University of Birmingham · Oropharyngeal CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05000710Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapySheba Medical Center · Metastatic or Locally Advanced NSCLCActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05927142Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic...Joachim Aerts, MD PhD · Metastatic Pancreatic CancerActive, not recruitingAIMCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT05065554ACALA-R In Predominantly Demyelinating IgM Mediated NeuropathyShayna Sarosiek, MD · IgM MGUSActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 6, 2026Sponsor estimateNo phase registeredNCT05817110Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.AstraZeneca · Lung MalignancyActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2026Sponsor estimatePhase 3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc. · NMOSDActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2026Sponsor estimatePhase 2NCT07222917A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in...AstraZeneca · Chronic Kidney Disease and HypertensionActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2026Sponsor estimateNo phase registeredNCT06712563Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care SettingAstraZeneca · Pulmonary Disease, Chronic ObstructiveActive, not recruitingAZNLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 3NCT05692180A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and...AstraZeneca · AsthmaActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT06490107Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTCCancer Institute and Hospital, Chinese Academy of Medical Sciences · Biliary Tract CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT00223145Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy AloneAbdenour Nabid · Prostate CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT00223171Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate CancersUniversité de Sherbrooke · Prostate CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1/Phase 2NCT03594396Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerSeoul National University Hospital · Breast NeoplasmsActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04462328Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaWashington University School of Medicine · Primary Central Nervous System LymphomaActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT04602533Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)Michael Hopp · Small Cell Lung Cancer Limited StageActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06147037A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursAstraZeneca · Advanced Solid TumorActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06336330Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyAstraZeneca · Heart DiseasesActive, not recruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT04699838Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerMuhammad Furqan · Extensive Stage Small Cell Lung Cancer | AZNCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 2027Sponsor estimate | NCT05214183Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaNordic Lymphoma Group · MCL | AZNCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 2NCT04699838Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerMuhammad Furqan · Extensive Stage Small Cell Lung CancerActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2NCT05214183Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaNordic Lymphoma Group · MCLActive, not recruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 18 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.